clinical trials

An Ebola Therapy Two Decades in the Making

IRP Researcher Nancy Sullivan Led Development of Cutting-Edge Treatment

a volunteer receives an infusion of an experimental Ebola therapy during a phase I clinical trial

Twenty-four years before the novel coronavirus began spreading in Wuhan, China, an outbreak of another deadly virus burned through the city of Kikwit in what is now the Democratic Republic of Congo. Between January and August of 1995, 316 people are thought to have contracted Ebola, and 252 of them died. More than a decade later, a team of NIH infectious disease scientists would track down one of the survivors and use a sample of the individual’s blood to produce one of the first effective treatments for Ebola.

IRP Clinical Trials Provide Irreplaceable Hope

Volunteering for Studies Allows Me to Help Myself and Others

NIH research participant Noah Victoria in a patient room at the NIH Clinical Center

Watching my dad carry the luggage to the car has become an all-too-familiar sight. It’s time for my mom and me to head to the NIH again, another trip in a lifelong journey for answers. I give my dad a long hug goodbye, and then I watch him stand alone in the driveway as we back away. The gravel arduously aches and crunches under our tires, a sound as uncomfortable as my symptoms even on my good days — few as there are.

Shedding Light on the Deep Darkness of Depression

Dr. Carlos Zarate with a participant in a neuroimaging study

In 2016, more than one in twenty American adults and one in ten adolescents experienced at least one major depressive episode. For nearly 45,000 of these individuals, their condition was severe enough that it led them to take their own lives. Unfortunately, the medications currently available to treat depression are not always effective and can take up to six weeks to substantially reduce symptoms.

To improve treatment and accelerate symptom relief, IRP senior investigator Carlos Zarate Jr., M.D., is working towards the development of new medications for depression, along with the identification of new drug targets and objective measures called biomarkers that yield information about how a patient is responding to treatment. In recent years, his lab has extensively investigated and assessed the effects of the anesthetic drug ketamine on depression and suicidal thoughts. Many of the patients in his trials have had marked and rapid responses to ketamine, sometimes within a single day or just a couple of hours. 

On Tuesday, November 13, Dr. Zarate participated in a Reddit “Ask Me Anything” (AMA) to answer questions from the public about the way depression is currently treated and the latest efforts to develop cutting-edge therapies for the condition. Read on for some of the most interesting exchanges that took place or check out the full AMA on Reddit.

Smartphone Apps Show Promise for Assessing Multiple Sclerosis Symptoms

brain scan of a patient with multiple sclerosis

The three-quarters of Americans who own a smartphone use them not just for communicating but also keeping a calendar, playing games, scouring the Internet for funny cat memes, and — soon — maybe even evaluating their neurological health. A new study conducted by IRP and University of Maryland researchers has confirmed the potential of smartphone apps for gauging symptoms of the neurological disease multiple sclerosis.

Studying ADHD from Genes to the Brain Connectome

Contributed by an NIH clinical trial participant.

A magnetic resonance image (MRI) of a brain

My 8-year-old nephew Luke has a sixth-grade reading level, while still in the third grade. Yet, he often struggles to finish his chores. He carries a timer in his backpack to keep himself on task. His school provides Luke with special assistance, including extra time for tests and repeated, detailed instruction. The challenges arise because Luke, like his mother Rebecca, has attention-deficit/hyperactivity disorder (ADHD).

John and ALS: Participating in an NIH Clinical Study

“I kind of made it a mission of mine to find out as much as I can, what’s available out there as treatments, trials,” John says, “and just my way of giving back, whether it helps me directly or somebody who comes after me.”

Need for Speed

Reblog via The Children's Inn at NIH: Family Stories.

Travis Carpenter NF1

From Travis’ appearance and attitude, you’d never believe that, inside his body, many things are wrong. His legs are different lengths, his bones are prone to breaking, and he has a long, “deep” tumor running from his lower spine down across his hip to below his knee. He also has lower back pain from constant irritation to the nerves in his spine.

Meet Children's Inn Resident Connor O’Brien

Reblog via The Children's Inn at NIH: Family Stories.

Connor, Childrens Inn at NIH

In the words of Connor: “A lot of times treatment for cancer and chronic diseases is very difficult to sustain. A lot of times it hurts. A lot of times you have to be given anesthesia, invasive things like that. The Inn gives you somewhere to come home to, somewhere to end your day, a place where you can have closure. Thank you all for making sure we have The Inn to come home to.”